Arcutis Biotherapeutics: Betting Big On Zoryve [Seeking Alpha]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Seeking Alpha
The company has received FDA approval for its drug Zoryve and is expecting further label expansions and approvals. While the company has seen good financial results and share price growth, there are concerns about its reliance on a single drug and lack of pipeline beyond Zoryve. Thesis Taking into account Arcutis Biotherapeutics ( NASDAQ: ARQT ) mixed signs such as FY2023 good financial results, Zoryve sales and label expansions, share price volatility, and revenue reliance on a single drug, I rate Arcutis Biotherapeutics stock as a “Hold” at Recommended For You Recommended For You About ARQT Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Needham & Company LLC from $16.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Topical Drug Delivery Market Size to Hit USD 229.91 Bn by 2031 [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $17.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Arcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
ARQT
Earnings
- 5/14/24 - Beat
ARQT
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 5/3/24 - Form 4
- ARQT's page on the SEC website